A share price of Taysha Gene Therapies Inc [TSHA] is currently trading at $2.74, up 1.11%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TSHA shares have gain 4.58% over the last week, with a monthly amount glided 17.09%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Taysha Gene Therapies Inc [NASDAQ: TSHA] stock has seen the most recent analyst activity on July 11, 2025, when BofA Securities initiated its Buy rating and assigned the stock a price target of $8. Previously, BMO Capital Markets started tracking the stock with Outperform rating on June 27, 2024, and set its price target to $5. On April 09, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $9 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $1.50 on February 01, 2023. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $3 on January 27, 2023. Goldman downgraded its rating to Neutral for this stock on November 09, 2022, and downed its price target to $3. In a note dated March 09, 2022, Robert W. Baird initiated an Outperform rating and provided a target price of $26 on this stock.
Taysha Gene Therapies Inc experienced fluctuations in its stock price throughout the past year between $1.05 and $3.31. Currently, Wall Street analysts expect the stock to reach $18.67 within the next 12 months. Taysha Gene Therapies Inc [NASDAQ: TSHA] shares were valued at $2.74 at the most recent close of the market. An investor can expect a potential return of 581.39% based on the average TSHA price forecast.
Analyzing the TSHA fundamentals
Trailing Twelve Months sales for Taysha Gene Therapies Inc [NASDAQ:TSHA] were 7.22M which represents -32.51% decline. Gross Profit Margin for this corporation currently stands at 0.73% with Operating Profit Margin at -12.26%, Pretax Profit Margin comes in at -12.01%, and Net Profit Margin reading is -12.01%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -1.07 and Total Capital is -0.76. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Taysha Gene Therapies Inc [NASDAQ:TSHA] is 5.35. As well, the Quick Ratio is 5.35, while the Cash Ratio is 5.17. Considering the valuation of this stock, the price to sales ratio is 99.25, the price to book ratio is 10.20.
Transactions by insiders
Recent insider trading involved Manning Paul B, 10% Owner, that happened on May 30 ’25 when 0.75 million shares were purchased.
